MedTrace Logo

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

NCT05229237 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-02-08

No results posted yet for this study

Summary

1. To evaluate the effectiveness of Conbercept for PCV patients.
2. To describe the characteristics of PCV.
3. To describe the adverse events (AE) of Conbercept in the treatment of PCV.
4. Todescirbe the real situation and prognosis of PCV patients in our country.

Conditions

  • Polypoidal Choroidal Vasculopathy
  • Conbercept

Interventions

DRUG

Conbercept

Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Youxin Chen, Professor · Peking Union Medical College Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2021-06-05
Completion
2021-12-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229237 on ClinicalTrials.gov